Endo, Advanz Pharma Partner To Commercialize Xydalba In Canada

Endo International plc (ENDP) said that its subsidiary, Endo Ventures Limited, has reached a definitive agreement with Correvio International Sàrl entity, a subsidiary of Advanz Pharma, to commercialize and distribute on an exclusive basis Xydalba or dalbavancin hydrochloride in Canada.

As per the terms of the deal, Endo Ventures will be responsible for the distribution, sales, marketing, medical affairs, pricing and reimbursement activities in Canada. Endo Venture Limited's affiliate, Paladin Labs, an operating company of Endo International, will perform those activities.

Advanz Pharma will be responsible for supplying the drug. Paladin Labs is targeting to launch the product in 2021. Advanz Pharma will provide additional business updates as and when appropriate.

Xydalba was approved by Health Canada in September 2018 for the treatment of Acute Bacterial Skin and Skin Structure Infections in adults caused by susceptible isolates of gram-positive microorganisms, including methicillin resistant Staphylococcus aureus.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
General Motors will start replacing defective battery modules in Chevrolet Bolt EVs and EUVs with new modules. The replacement battery modules will be shipped to dealers as soon as mid-October, the automaker said in a statement. CVS Health is set to recruit qualified candidates to fill 25,000 clinical and retail jobs during a one-day national career event on Friday, September 24. This will enable CVS to meet the high demand for pharmacists, pharmacy technicians, nurses, and retail store associates to support flu season, COVID-19 vaccinations and testing. Twitter, Inc. (TWTR) announced Monday that it has entered into a binding agreement to settle the consolidated class action lawsuit commenced in 2016 in the United States District Court for the Northern District of California. Under the terms of the proposed settlement, Twitter will pay $809.5 million...
Follow RTT